Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported a 12.9% increase in revenues to NOK 138.9 million in the third quarter of 2025.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million, a 12.9% increase from Q3 2024
- Gross margin: 37.5%, compared to 37.1% in Q3 2024
- Adjusted EBITDA: NOK 11.3 million, compared to NOK 8.6 million in 2024
The overall revenues performance was driven by increases in all three business areas.
Author's summary: Navamedic ASA reports 12.9% revenue growth.